NDAORALSOLUTION
Approved
Jun 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of Action Although the etiology of cognitive impairment in Alzheimer's disease (AD) is not fully understood, it has been reported that acetylcholine-producing neurons degenerate in the brains of patients with Alzheimer's disease. The degree of this cholinergic loss…
Indications (1)
Clinical Trials (3)
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease
Started Jun 2004
344 enrolled
Alzheimer Disease
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
Started Dec 2003
415 enrolled
DementiaAlzheimer Disease
A Study of the Effectiveness and Safety of Galantamine Hydrobromide on Cognitive Impairment in Patients With Schizophrenia.
Started Mar 2003
107 enrolled
Schizophrenia